ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES

Abstract: Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

Description: TITLE OF THE INVENTION ARYLTfflAZOLJDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES FIELD OF THE INVENTION The instant invention is concerned with arylthiazo dinediones, aryloxazohnediones, and pharmaceutically acceptable salts thereof, which are useful as therapeutic compounds BACKGROUND OF THE INVENTION Diabetes refers to a disease process deπved from multiple causative factors and characterized by elevated levels of plasma glucose or hyperglycemia Uncontrolled hyperglycemia is associated with increased and premature mortality due to an increased πsk for microvascular and macrovascular diseases, including nephropathy, neuropathy, retinopathy, hypertension, stroke, and heart disease Therefore, control of glucose homeostasis is a critically important approach for the treatment of diabetes There are two generally recognized forms of diabetes In type I diabetes, or insulin-dependent diabetes mel tus (IDDM), patients produce little or no msulm, the hormone which regulates glucose utilization. In type II diabetes, or noninsulm dependent diabetes melhtus (NIDDM), patients often have plasma insulin levels that are the same or even elevated compared to nondiabetic humans, however, these patients have developed a resistance to the msulm stimulating effect on glucose and hpid metabolism in the mam insulm-sensitive tissues, muscle, liver and adipose tissue and the plasma insulin levels are insufficient to overcome the pronounced insulin resistance Insulin resistance is not pπmaπly due to a diminished number of insulin receptors but to a post-insuhn receptor binding defect that is not yet understood This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate msulm repression of hpolysis in adipose tissue and of glucose production and secretion in liver The common treatments for NIDDM, which have not changed substantially in many years, are all with limitations. While physical exercise and reductions in dietary intake of caloπes will dramatically improve the diabetic condition, compliance with this treatment is very poor because of well-entrenched sedentary lifestyles and excess food consumption, especially of high fat-contaming food Increasing the plasma level of insulin by administration of sulfonylureas (e g tolbutamide, ghpizide) which stimulate the pancreatic β— cells to secrete more insulin or by injection of msulm after the response to sulfonylureas fails will result in high enough insulin concentrations to stimulate the very insulin-resistant tissues However, dangerously low levels of plasma glucose can result from these last two treatments and increasing insulin resistance due to the even higher plasma insulin levels could occur The biguanides increase insulin sensitivity resulting in some correction of hyperglycemia However, the two biguanides, phenformin and metformin, can induce lactic acidosis and nausea/diarrhea, respectively The g tazones (l e 5-benzylthιazohdιne-2,4-dιones) are a more recently descnbed class of compounds with potential for a novel mode of action in ameliorating many symptoms of NIDDM. These agents substantially increase insulin sensitivity in muscle, liver and adipose tissue in several animal models of NIDDM resulting in partial or complete correction of the elevated plasma levels of glucose without occurrence of hypoglycemia. Hyperlipidemia is a condition which is characteπzed by an abnormal increase in serum hpids, such as cholesterol, tπglyceπdes and phosphohpids These hpids do not circulate freely in solution in plasma, but are bound to proteins and transported as macromolecular complexes called lipoproteins See the Merck Manual, 16th Ed. 1992 (see for example pp 1039-1040) and "Structure and Metabolism of Plasma Lipoproteins" in Metabolic Basis of Inherited Disease, 6th Ed. 1989, pp 1129-1138 One form of hyperlipidemia is hypercholesterolemia, characteπzed by the existence of elevated LDL cholesterol levels The initial treatment for hypercholesterolemia is often to modify the diet to one low in fat and cholesterol, coupled with appropπate physical exercise, followed by drug therapy when LDL- loweπng goals are not met by diet and exercise alone. LDL is commonly known as the "bad" cholesterol, while HDL is the "good" cholesterol. Although it is desirable to lower elevated levels of LDL cholesterol, it is also desirable to increase levels of HDL cholesterol. Generally, it has been found that increased levels of HDL are associated with lower πsk for coronary heart disease (CHD) See, for example, Gordon, et al., Am. J. Med., 62, 707-714 (1977); Stampfer, et al., N. England J. Med., 325, 373-381 (1991); and Kannel, et al., Ann. Internal Med , 90, 85-91 (1979). An example of an HDL raising agent is nicotinic acid, but the quantities needed to achieve HDL raising are associated with undesirable effects, such as flushing Dyshpidemia is another term that is used to descπbe a combination of conditions that are associated with type II diabetes Dyshpidemia refers generally to elevated LDL, elevated tπglyceπdes and reduced HDL Peroxisome pro ferators are a structurally diverse group of compounds that when administered to rodents elicit dramatic increases in the size and number of hepatic and renal peroxisomes, as well as concomitant increases in the capacity of peroxisomes to metabolize fatty acids via increased expression of the enzymes of the beta-ox idati on cycle Compounds of this group include but are not limited to the fibrate class of hyperhpidemic drugs, herbicides and phthalate plasticizers Peroxisome proliferation is also tπggered by dietary or physiological factors such as a high-fat diet and cold acclimatization Three sub-types of peroxisome prohferator activated receptor (PPAR) have been discovered and descπbed; they are peroxisome prohferator activated receptor alpha (PPARoc), peroxisome prohferator activated receptor gamma (PPARγ) and peroxisome prohferator activated receptor delta (PPARδ) Identification of PPARα, a member of the nuclear hormone receptor superf amily activated by peroxisome prohferators, has facilitated analysis of the mechanism by which peroxisome prohferators exert their pleiotropic effects. PPARα is activated by a number of medium and long-chain fatty acids, and it is involved m stimulating β-oxidation of fatty acids PPARα is also involved with the activity of fibrates and fatty acids m rodents and humans Fibπc acid deπvatives such as clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and etofibrate, as well as gemfibrozil, produce a substantial reduction in plasma tπglyceπdes along with moderate reduction in LDL cholesterol, and they are used particularly for the treatment of hypertπglyceπdemia. The PPARγ receptor subtypes are involved in activating the program of adipocyte differentiation and are not involved in stimulating peroxisome proliferation in the liver. There are two isoforms of PPARγ : PPARγl and PPARγ2, which differ only in that PPARγ2 contains an additional 28 amino acids present at the amino terminus. The DNA sequences for the isotypes are descπbed in Elbrecht, et al., BBRC 224 ;431-437 (1996) In mice, PPARγ2 is expressed specifically fat cells. Tontonoz et al, Cell 79. 1147-1156 (1994) provide evidence to show that one physiological role of PPARγ2 is to induce adipocyte differentiation. As with other members of the nuclear hormone receptor superfamily, PPARγ 2 regulates the expression of genes through interaction with other proteins and binding to hormone response elements for example in the 5' flanking regions of responsive genes An example of a PPARγ2 responsive gene is the tissue-specific adipocyte P2 gene Although peroxisome prohferators, including the fibrates and fatty acids, activate the transcπptional activity of PPAR's, only prostaglandin J2 deπvatives have been identified as natural gands of the PPARγ subtype, which also binds thiazohdmedione antidiabetic agents with high affinity The human nuclear receptor gene PPARδ (hPPARδ) has been cloned from a human osteosarcoma cell cDNA library and is fully descπbed in A Schmidt et al , Molecular Endocrinology, 6 1634-1641 (1992) It should be noted that PPARδ is also referred to in the literature as PPARβ and as NUC1, and each of these names refers to the same receptor, in Schmidt et al the receptor is referred to as NUC1 In WO96/01430, a human PPAR subtype, hNUClB, is disclosed The ammo acid sequence of hNUClB differs from human PPARδ (referred to therein as hNUCl) by one ammo acid, I e , alanine at position 292 Based on in vivo expeπments descπbed therein, the authors suggest that hNUClB protein represses hPPARa and thyroid hormone receptor protein activity It has been disclosed m WO97/28149 that agonists of PPARδ are useful in raising HDL plasma levels WO97/27857, 97/28115, 97/28137 and 97/27847 disclose compounds that are useful as antidiabetic, antiobesity, anti- atherosclerosis and antihyperlipidemic agents, and which may exert their effect through activation of PPARs It has been suggested that ghtazones exert their effects by binding to the peroxisome prohferator activated receptor (PPAR) family of receptors, controlling certain transcπption elements having to do with the biological entities listed above See Hulm et al , Current Pharm Design (1996) 2, 85-102 Most of the ghtazones that have been descπbed m the literature are believed to bind almost exclusively to the PPARγ subtype All the ghtazones that have progressed to clinical tπals in human, and almost all of the ghtazones that have been reported m the literature have the molecular motif of an aryl group attached to the 5-posιtιon of thiazohdmedione via a one carbon spacer Although several compounds having a 4-(oxy)phenyl group directly attached to the 5-posιtιon of thiazohdmedione have been prepared and tested as potential antidiabetic agents, they have been stated to lack hypoglycemic activity Thus, the compound 5-[4-[2-(2-benzoxazolylmethylamιno) ethoxy]phenyl]-2,4-thιazohdmedιone (1) showed no antihyperglycemic activity in ob/ob mice, and subsequent studies showed this compound to require relatively high amounts for PPARγ activation. (Cantello et al, J Med Chem , 1994, 37-3977-3985 and Willson et al. J Med Chem , 1996, 39"665-668). The compound 5-[4-(phenylethoxy)phenyl]-2,4-thιazohdιnedιone (2) showed no antihyperglycemic effect in diabetic mouse model, even though it may have aldose reductase inhibitory activity. (Sohda et al, Chem. Pharm. Bull., 1982, 30:3580-3600, and Sohda et al, Chem. Pharm Bull. 1982, 30:3601-3616). Examples of other phenylthiazohdinedione aldose reductase inhibitors include 5-[4-(4-chloro- phenoxy)phenyl]-2,4-thιazohdιnedιone, 5-[4-(4-chlorobenzyloxy)phenyl]-2,4- thiazohdinedione, 5-[4-(2-pyπdylethoxy)phenyl]-2,4-thιazohdιnedιone, 5-[4-(6- methyl-2-pyπdylethoxy)phenyl]-2,4-thιazohdιnedιone, and 5-[4-(2- thιenylethoxy)phenyl]-2,4-thιazohdιnedιone. (Sohda et al, Chem. Pharm. Bull., 1982, PCT Published Application WO97/22600 discloses antihyperglycemic 5-[3-(carboxamιdo)phenyl]-2,4-thιazohdmedιones of the formula Some oxazo dinedione compounds having the oxazohdinedione πng bound directly to the aryl group have been synthesized and have been found to have some hypoglycemic activity See for example (1) R Dow et al , J Med Chem , 34, 1538-1544 (1991), (2) R Schnur, et al , J Med Chem 29, 770-778 (1986), (3) US Patent 4,367,234, (4) US Patent 4,342,771, and (5) US Patent 4,332,952 The present inventors have found that certain substituted 5-aryl-2,4- thiazohdinediones and 5-aryl-2,4-oxazohdιnedιones having at least one cycloalkyl or heterocychc substituent on the πng Ar2 of Formula I are potent agonists of PPAR, in particular the α and/or γ subtypes, and especially the γ subtype or both the α/γ subtypes These compounds are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, dyshpidemia, hyperlipidemia (including hypercholesterolemia and hypertπglyceπdemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α and/or γ mediated diseases, disorders and conditions SUMMARY OF THE INVENTION The present invention provides compounds having the structure of Formula I CH 2 -(CH 2 ) n -CH 2 -X-Ar 2 wherein Arl is (1) arylene or (2) heteroarylene, where said arylene or heteroarylene is optionally substituted with from 1 to 4 groups independently selected from R a , R, or a mixture thereof Ar2 is (1) aryl or (2) heteroaryl, wherein said aryl or heteroaryl is substituted with 1-2 groups independently selected from R, provided that if only one cycloalkyl is present on Ar2, the cycloalkyl is not in the ortho position, and said aryl or heteroaryl is optionally further substituted with from 1-3 groups independently selected from R a , X and Y are independently O, S, N-Rb, or CH2, n is 0 to 3. R is (1) C3-8 cycloalkyl, optionally substituted with 1-15 halogen atoms, 1-3 groups independently selected from Ci-6 alkyl, and mixtures thereof; or (2) a 3-10 membered heterocycle containing one or more heteroatoms selected from N, S, O, and SO2, said heterocycle being optionally substituted with 1-3 halogen atoms or one to three Ci -6 alkyl groups, Ra is (1) Ci-15 alkanoyl, (2) Ci-15 alkyl, (3) C2-15 alkenyl, (4) C2-15 alkynyl, (5) halo, (6) ORb, (7) aryl, or (8) heteroaryl, wherein said alkyl, alkenyl, alkynyl, and alkanoyl are optionally substituted with from 1-5 groups selected from R c , and said aryl and heteroaryl are optionally substituted with 1 to 5 groups selected from R ; R D ιs (1) hydrogen, (2) Ci-ioalkyl, (3) C2-I0alkenyl, (4) C2-loalkynyl, (5) aryl, (6) heteroaryl, (7) aryl Ci-15 alkyl, (8) heteroaryl Ci-15 alkyl, (9) C 1-15 alkanoyl, (10) C3-8 cycloalkyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from Re, and said cycloalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from Rd, RC is (1) halo, (2) aryl, (3) heteroaryl ; (4) CN, (5) NO 2 , (6) OR f , (7) S(O) m Rf, m = 0, 1 or 2, provided that R f is not (8) NR f R f , (9) NR f COR f , (10) NR f CO2R f , (11) NR f CON(R f )2, (12) NR f SO2R f , provided that Rf is not H, (13) COR f , (14) CO 2 R f , (15) CON(R f )2, (17) OCON(R f )2, or (18) C3-8cycloalkyl, wherem said cycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 3 groups of halo or Ci-6 alkyl; Rd is (1) a group selected from Re, (2) Ci-10 alkyl, (3) C2-10 alkenyl, (4) C2-10 alkynyl, (5) aryl C -io alkyl, or (6) heteroaryl Ci-io alkyl, wherein said alkyl, alkenyl, alkynyl, aryl Ci-io alkyl, and heteroaryl Ci-io alkyl are optionally substituted with a group independently selected from R e ; Re is (1) halogen, (2) amino, (3) carboxy, (4) Ci-4alkyl, (5) Ci-4alkoxy, (6) hydroxy, (7) aryl, (8) aryl Ci-4 alkyl, or (9) aryloxy; Rf is (1) hydrogen, (2) Ci-io alkyl, (3) C2- 10 alkenyl, (4) C2-10 alkynyl, (5) aryl, (6) heteroaryl, (7) aryl Ci-15 alkyl, (8) heteroaryl Cι_i5 alkyl, (9) Ci-15 alkanoyl, (10) C3-8 cycloalkyl; wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkanoyl and cycloalkyl are optionally substituted with one to four groups independently selected from Re; or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION The invention has numerous preferred embodiments, including: compounds of Formula I wherein Z is sulfur, compounds of Formula I, wherein Z is O, compounds of Formula I wherein Arl is arylene optionally substituted with 1-4 groups independently selected from R a , R, or a mixture thereof, compounds of Formula I wherem Arl 1S phenylene optionally substituted with 1-2 groups independently selected from halogen and Cι_4 alkyl, compounds of Formula I wherem X and Y are independently CH2, O or S, compounds of Formula I in which n is 1 or 2, and compounds of Formula I wherein X and Y are each O or S The invention also compπses a subset of compounds having the structure of Formula I, wherem Ar2 is aryl, wherein said aryl is substituted with one Ra group in the position ortho to X and is further substituted with 1-2 groups independently selected from R and optionally 1-2 groups independently selected from Ra In a preferred embodiment of this subset, R a that is in the position ortho to X is selected from the group consisting of (1) C3-10 alkyl optionally substituted with 1-4 groups independently selected from halo and C3-6 cycloalkyl, (2) C3-10 alkenyl, or (3) C3-8 cycloalkyl In a preferred embodiment of the above subset of compounds, Ar2 is a phenyl πng In one embodiment of the last subset of compounds, two of the optional substituents R a are on adjacent carbon atoms on the Ar2 phenyl πng and are joined to form a 5- or 6-membered aromatic heterocychc πng fused to Ar2, said πng containing 1-2 heteroatoms independently selected from N, O, and S(O)m, where m is 0-2, said heterocychc πng and Ar2 together being substituted with 1-2 groups independently selected from R, one R a group in the position ortho to X, and optionally 1-2 additional groups independently selected from R a In preferred examples of this last embodiment, the aromatic heterocychc πng fused to Ar2 is selected from isoxazole, thiophene, thiophene S-oxide, thiophene S-dioxide, and furan A preferred embodiment compπses compounds of Formula I having the structure shown as Formula la- la wherein X, Y, Z, n, R, and R a are as previously defined More specific embodiments of the compounds having Formula lb include: compounds of Formula la where Z is S; compounds of Formula la where Z is O; compounds of Formula la where Y is S or O, and X is O; compounds of Formula la where one Ra group is ortho to X and is C3- 4 alkyl; compounds of Formula la where n is 1 or 2; and compounds of Formula la where Z is O or S; (2) S, and one group Ra is ortho to X and is C3-4 alkyl A highly preferred embodiment of this last group of compounds includes compounds where Z is O and R is cyclohexyl Specific examples of compounds of this invention are provided herein in Examples 1-12 by name and by structural formula The invention further includes pharmaceutical compositions compπs g any of the compounds described above and a pharmaceutically acceptable earner The compounds as defined above are useful in the following methods of treating, controlling, and preventing diseases, as well as other diseases not listed below (1) a method for treating or controlling diabetes melhtus in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, (2) a method for treating, controlling or preventing hyperglycemia in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, (3) a method for treating, controlling or preventing hyperlipidemia in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, (4) a method for treating, controlling or preventing obesity in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, (5) a method for treating, controlling or preventing hypercholesterolemia in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, (6) a method for treating, controlling or preventing hypertπglyceπdemia in a mammal which compπses administeπng to the mammal a therapeutically effective amount of a compound of Formula I, and (7) a method for treating, controlling or preventing dyshpidemia in a mammal which compπses admmisteπng to the mammal a therapeutically effective amount of a compound of Formula I Definitions "Alkyl", as well as other groups having the prefix "alk", such as alkoxy, alkanoyl, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. "Alkenyl" means carbon chains which contain at least one carbon- carbon double bond, and which may be linear or branched or combinations thereof. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1- propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like. "Alkynyl" means carbon chains which contain at least one carbon- carbon tπple bond, and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl, propargyl, 3-methyl-l-pentynyl, 2-heptynyl and "Cycloalkyl" means mono- or bicyclic saturated carbocyc c πngs, each having from 3 to 10 carbon atoms. The term also includes a monocyc c πng fused to an aryl group in which the point of attachment is on the non-aromatic portion. Examples of cycloalkyl include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. "Aryl" (and "arylene") means mono- or bicyclic aromatic πngs containing only carbon πng atoms. The term also includes an aryl group fused to a monocychc cycloalkyl or monocychc heterocychc group in which the pomt(s) of attachment is on the aromatic portion. "Heterocycle" and "heterocychc" means a fully or partially saturated πng containing at least one heteroatom selected from N, S and O, each of said πngs having from 3 to 10 atoms Examples of aryl include phenyl, naphthyl. mdanyl, mdenyl, tetrahydronaphthyl, 2,3-dιhydrobenzofuranyl. benzopyranyl, 1,4-benzodιoxanyl, benzoxazolyl, benzisoxazolyl, and the like Examples of heterocycles include tetrahydrofuran, piperaz e, and morphohne "Heteroaryl" (and heteroarylene) means a mono-, bi- or tπcychc aromatic πng containing at least one πng heteroatom selected from N, O and S (including SO and SO2), with each πng containing 5 to 6 atoms. Examples of heteroaryl include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyπdyl. oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, lmidazolyl, tπazolyl, tetrazolyl, furanyl, tπazinyl, thienyl, pyπmidyl, pyπdaz yl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl (including S-oxide and dioxide), furo(2,3-b)pyπdyl, quinolyl, indolyl, isoquinolyl, dibenzofuran and the "Halogen" includes fluoπne, chloπne, bromine and iodine. The term "ortho-substituted" means the substituent is attached to a πng atom that is adjacent to the point of attachment to the backbone of the molecule. "Meta-substituted" and "para-substituted" are defined analogously based on the point of attachment of the πng to the backbone of the molecule The term "composition", as in pharmaceutical composition, is intended to encompass a product compπsing the active mgredιent(s), and the inert mgredιent(s) that make up the earner, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable earner. Optical Isomers - Diastereomers - Geometnc Isomers - Tautomers Compounds of Formula I may contain one or more asymmetπc centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomenc mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeπc forms of the compounds of Formula I. Some of the compounds descnbed herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometnc isomers. Some of the compounds descπbed herein may exist with different points of attachment of hydrogen, referred to as tautomers Such an example may be a ketone and its enol form known as keto-enol tautomers The individual tautomers as well as mixtures thereof are encompassed with compounds of Formula I Compounds of the Formula I may be separated into diastereoisomeπc pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent Alternatively, any enantiomer of a compound of the general Formula I or la may be obtained by stereospecific synthesis using optically pure starting matenals or reagents of known configuration Salts The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids Salts deπved from inorganic bases include aluminum, ammonium, calcium, copper, feme, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates Salts deπved from pharmaceutically acceptable organic non-toxic bases include salts of pπmary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as argmine, beta e, caffeine, chohne, N,N '- dibenzylethylenediamine, diethylamine, 2-dιethylammoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamme, N-ethyl-morphohne, N- ethylpipendine, glucamme, glucosamine, histidine, hydrabam e, isopropylamine, lysine, methylglucamme, morphohne, piperazme, pipeπd e, polyamine resins, procaine, puπnes, theobromine, tπethylamine, tπmethylamme, tπpropylamine, tromethamme, and the like When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citπc, ethanesulfonic, fumaπc, glucomc, glutamic, hydrobromic, hydrochloπc, lsethionic, lactic, maleic, malic, mande c, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphonc, succmic, sulfuπc, tartaπc, p-toluenesulfonic acid, and the like Particularly preferred are citπc, hydrobromic, hydrochloπc, maleic, phosphonc, sulfuπc, and tartaπc acids It will be understood that, as used herein, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts Utilities Compounds of the present invention are potent agonists of vaπoius peroxisome prohferator activator receptor subtypes, particularly PPARα and/or PPARγ Compounds of the present invention may be selective agonists of one receptor subtype, e g PPARγ agonists, or they may be agonists of more than one receptor subtypes, e g dual PPARα/γ agonists Compounds of the present invention are useful in treating, controlling or preventing diseases, disorders or conditions, wherein the treatment is mediated by the activation of an individual PPAR subtype (α or γ), or a combination of PPAR subtypes (e g α/γ) Thus one aspect of the present invention provides a method for the treatment, control or prevention of such diseases, disorders, or conditions in a mammal which compnses administeπng to such mammal a therapeutically effective amount of a compound of Formula I The diseases, disorders or conditions for which compounds of the present invention are useful in treating, controlling or preventing include, but are not limited to, (1) diabetes melhtus, (2) hyperglycemia, (3) obesity, (4) hyperlipidemia, (5) hypertπglycendemia, (6) hypercholesterolemia (including raising HDL levels), (7) atherosclerosis, (8) vascular restenosis, (9) lrπtable bowel syndrome, (10) pancreatitis, (11) abdominal obesity, (12) adipose cell tumors, (13) adipose cell carcinomas such as liposarcoma, (14) dyshpidemia, and (15) other disorders where msulm resistance is a component including Syndrome X and ovaπan hyperandrogenism (polycystic ovanan syndrome) Also included are inflammatory diseases, such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis Another aspect of the invention provides a method for the treatment, control, or prevention of hypercholesterolemia which compπses administenng to a mammal in need of such treatment a therapeutically effective amount of an agonist of both PPARα and PPARγ (PPARα/γ dual agonist) The dual agonist may be advantageously administered with a cholesterol biosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor such as lovastat , simvastatin, pravastatin, fluvastatin, atorvastatm and nvastatm Administration and Dose Ranges Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like Preferably compounds of Formula I are administered orally The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the seventy of the condition being treated Such dosage may be ascertained readily by a person skilled in the art When treating or preventing diabetes melhtus and or hyperglycemia or hypertπglycendemia or other diseases for which compounds of Formula I are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0 1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or m sustained release form For most large mammals, the total daily dosage is from about 1 0 milligrams to about 1000 milligrams, preferably from about 1 milligrams to about 50 milligrams In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams This dosage regimen may be adjusted to provide the optimal therapeutic response Pharmaceutical Compositions Another aspect of the present invention provides pharmaceutical compositions which compπses a compound of Formula I and a pharmaceutically acceptable earner The pharmaceutical compositions of the present invention compπse a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable earner and optionally other therapeutic ingredients The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and seventy of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical earner according to conventional pharmaceutical compounding techniques. The earner may take a wide vanety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) In prepanng the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavonng agents, preservatives, coloπng agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or earners such as starches, sugars, microcrystallme cellulose, diluents, granulating agents, lubπcants, binders, disintegrating agents and the like m the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical earners are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be vaπed and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray. The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubπcant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or sacchann When a dosage unit form is a capsule, it may contain, in addition to mateπals of the above type, a liquid earner such as a fatty oil Vanous other mateπals may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavonng such as cherry or orange flavor. Compounds of formula I may also be administered parenterally Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include stenle aqueous solutions or dispersions and stenle powders for the extemporaneous preparation of stenle mjectable solutions or dispersions. In all cases, the form must be stenle and must be fluid to the extent that easy syπngabihty exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bactena and fungi. The earner can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Combination Therapy Compounds of Formula I may be used in combination with other drugs that may also be useful in the treatment, prevention, suppression or amelioration of the diseases or conditions for which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition m unit dosage form containing such other drugs and the compound of Formula I is preferred. It is also contemplated that when used in combination with one or more other active ingredients, the compound of the present invention and the other active ingredients may be used lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of Formula I Examples of other active ingredients that may be combined with a compound of Formula I, either administered separately or in the same pharmaceutical compositions, include, but are not limited to (a) insulin sensitizers including (1) PPARγ agonists such as the ghtazones (e g troghtazone, pioghtazone, enghtazone, MCC-555, BRL49653 (rosightazone), and the like), and compounds disclosed in WO97/27857, 97/28115, 97/28137 and 97/27847; (n) biguanides such as metformm and phenformm, (b) insulin or insulin mimetics, (c) sulfonylureas such as tolbutamide and ghpizide, or related mateπals, (d) α-glucosidase inhibitors (such as acarbose), (e) cholesterol loweπng agents such as (I) HMG-CoA reductase inhibitors (lovastatm, simvastatin and pravastatin, fluvastatin, atorvastatm, nvastatm and other statins), (n) sequestrants (cholestyram e, colestipol and a dialkylammoalkyl denvatives of a cross-linked dextran), (in) nicot yl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists such as fenofibnc acid denvatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) inhibitors of cholesterol absoφtion for example beta-sitosterol and (acyl CoA:cholesterol acyltransferase) inhibitors for example mehnamide and (vi) probucol; (f) PPARδ agonists such as those disclosed in WO97/28149, (g) antiobesity compounds such as fenfluramme, dexfenfluramme, phentiramine, sulbitramme, or stat, neuropeptide Y5 inhibitors, and β3 adrenergic receptor agonist, (h) eal bile acid transporter inhibitor. BIOLOGICAL ASSAYS A. White Adipose Tissue in vitro Assay This assay measures the efficacy of the instant compounds to enhance the insulin activation of l^C-glucose incorporation into glycogen in white adipose tissue (WAT) in a 5 hour completely in vitro system. All procedures are performed in medium 199 containing 1% bovine serum albumen, 5 mM HEPES, and antibiotic (100 units/ml penicillin, 100 μg/ml streptomycin sulfate, 0 25 μg/ml amphoteπcm B), hereafter called culture medium Epididimyl fat pads are minced with scissors into small fragments , approximately 1 mm in diameter Minced WAT fragments (100 mg) are incubated in a total volume of 0 9 ml culture medium containing 1 mU/ml insulin and test compound in tissue culture incubator at 37°C with 5% CO2 with orbital shaking for 3 hours l^Q-iabeled glucose is added and incubation continued for 2 hours Tubes are centnfuged at low speed, mfranatant is removed and 1 M NaOH is added Incubation of alkali-treated WAT for 10 minutes at 60°C solubi zes tissue Resulting tissue hydrolysate is applied to Whatman filter paper stπps which are then πnsed in 66% ethanol followed by 100% acetone which removes unincorporated 14c-glucose from bound 14c_giy CO g en dned paper is then incubated in solution of amyloglucosidase to cleave glycogen into glucose Scintillation fluid is added and samples are counted for ^C activity Test compounds that resulted ^C activity substantially above incubations with insulin alone are considered active insulin-enhancing agents Active compounds were titrated to determine the compound concentration which resulted in 50% of maximum enhancement of msulm activation and were termed EC50 values B Gal-4 hPPAR Transactivation Assays (a) Plasmids The chimeπc receptor expression constructs, pcDNA3-hPPARγ/GAL4, pcDNA3-hPPARδ/GAL4, pcDNA3-hPPARα/GAL4 were prepared by inserting the yeast GAL4 transcπption factor DBD adjacent to the hgand binding domains (LBDs) of hPPARγ, hPPARδ, hPPARα, respectively The reporter construct, pUAS(5X)-tk- luc was generated by inserting 5 copies of the GAL4 response element upstream of the herpes virus minimal thymidine kinase promoter and the luciferase reporter gene pCMV-lacZ contains the galactosidase Z gene under the regulation of the cytomegalovirus promoter (b) Cell culture and Transactivation Assays COS-1 cells were seeded at 12 X 10 cells/well in 96 well cell culture plates in high glucose Dulbecco's modified Eagle medium (DMEM) containing 10% charcoal stnpped fetal calf serum (Gemini Bio-Products, Calabasas, CA), nonessential ammo acids, 100 units/ml Penicillin G and 100 mg/ml Streptomycin sulfate at 37 °C in a humidified atmosphere of 10% CO2 After 24 h, transfections were performed with Lipofectamme (GEBCO BRL, Gaithersburg, MD) according to the instructions of the manufacturer. Bπefly, transfection mixes for each well contained 0.48 μl of Lipofectamme, 0.00075 μg of pcDNA3-PPAR/GAL4 expression vector, 0.045 μg of pUAS(5X)-tk-luc reporter vector and 0.0002 μg of pCMV-lacZ as an internal control for transactivation efficiency Cells were incubated in the transfection mixture for 5 h at 37° C in an atmosphere of 10% CO2 The cells were then incubated for -48 h in fresh high glucose DMEM containing 5% charcoal stnpped fetal calf serum, nonessential amino acids, 100 units/ml Penicillin G and 100 mg/ml Streptomycin sulfate ± increasing concentrations of test compound. Since the compounds were solubihzed in DMSO, control cells were incubated with equivalent concentrations of DMSO; final DMSO concentrations were < 0.1%, a concentration which was shown not to effect transactivation activity Cell lysates were produced using Reporter Lysis Buffer (Promega, Madison, WI) according to the manufacturer's instructions. Luciferase activity in cell extracts was determined using Luciferase Assay Buffer (Promega, Madison, WI) an ML3000 luminomεter (Dynatech Laboratoπes, Chantilly, VA). β-galactosidase activity was determined using β-D-galactopyranoside (Calbiochem, San Diego, CA). C In Vivo Studies Male db/db mice (10-11 week old C57B1/KFJ, Jackson Labs, Bar Harbor, ME) were housed 5/cage and allowed ad lib access to ground Puπna rodent chow and water The animals, and their food, were weighed every 2 days and were dosed daily by gavage with vehicle (0 5% carboxymethylcellulose) ± test compound at the indicated dose Drug suspensions were prepared daily Plasma glucose, and tπglycende concentrations were determined from blood obtained by tail bleeds at 3-5 day intervals dunng the study penod Glucose, and tπglycende, determinations were performed on a Boehnnger Mannheim Hitachi 911 automatic analyzer (Boehπnger Mannheim, Indianapolis, IN) using hepaπnized plasma diluted 1 6 (v/v) with normal saline Lean animals were age-matched heterozygous mice maintained in the same manner Methods of Synthesis Compounds of formula I may be prepared according to the methods outlined in the schemes The vanables in the schemes, unless otherwise specified, have the same meanings as defined above under formula I The intermediates and starting mateπals in Schemes 1-4 are wπtten with respect to methylesters, but other esters (e g C1-C15 esters) can also be used, as well as tnalkyl silane groups attached to the carboxyl Similarly, other acids, bases, halogenating agents and solvents can be used for many of the reactions in Schemes 1-4, as will be readily determined by practitioners in the field Scheme 1 H 3 COOC-CH 2 - Ar 1 — Y-CH 2 - (CH 2 ) n -CH X-Ar 2 (Al) a. LiHMDS, THF, TMSCI, NBS b. when Z= S, thiourea, methoxyethanol, HCI, reflux (CH 2 ) n -CH 2 -X-Ar 2 Alpha-bromination of an arylacetate ester intermediate Al with a halogenating agent (e.g N-bromosuccinimide) in the presence of a base produces a halo intermediate which may be πng-closed with thiourea (Z = S) in the presence of aqueous strong acid or sodium acetate in an alcoholic solvent such as 2- methoxyethanol at elevated temperatures to give the title aryl-thiazohdmones (I; Z=S) Scheme 2 HX— Ar 2 (SI) H 3 COOC-CH 2 -Ar 1 — YH + L-H 2 C- (CH^ -CH^X— Ar 2 (B2) (Cl) Cs 2 C0 3 , DMF H 3 COOC-CH 2 - Ar 1 — Y-CH 2 - (CH 2 ) n -CH^X— Ar 2 (Al) Cs 2 C0 3 , DMF H 3 COOC-CH 2 -Ar 1 — Y-CH 2 - (CH 2 ) n -CH 2 -L + HX-Ar 2 (C2) (Bl) L-H 2 C- (CH 2 ) n -CH 2 — L' (I) H 3 COOC-CH 2 -Ar 1 — YH (B2) L and U are same or different leaving groups Scheme 2 shows the synthesis of intermediate Al, which contains an Arl moiety and an Ar2 moiety connected by a >4 atom tether. Intermediate Al may be prepared by convergent synthesis by first attaching the tether T having two terminal leaving groups to either Arl 0 r Ar2; in T, L and L' represent independently of each other a conventional leaving group such as halide (preferably bromide) and sulfonyloxy (e.g mesylate or tosylate). Treatment of the tethered molecule Cl or C2 with the other aryl moiety B2 or Bl, respectively in the presence of an inorganic base (e.g CS2CO3) in DMF solution provides the tethered arylacetate ester intermediate Al The starting matenal T, B_l, and B2 are either commercially available or may be prepared using known organic synthesis procedures Compounds of formula B2 may be prepared according to the methods descnbed in published PCT Applications 97/27857, 97/28115 and 97/28137. Scheme 3 OH I H.COOC CH-Ar 1 — YH + L-H 2 C-(CH 2 ) n -CH 2 -χ— Ar (B3) (Cl) Cs CO-,, DMF OH I H 3 COOC-CH-Ar 1 — Y— CH 2 -(CH 2 ) n -CH 2 -χ— Ar (A2) toluene , ethanol, In Scheme 3 an appropπately substituted mandehc acid ester B3 is reacted with the Ar2 denvative having a leaving group L, Cl, the presence of an inorganic base such as cesium carbonate. The resulting product A2 is cyc zed with urea in the presence of a base such as sodium methoxide to form the desired product (I; Z=O). Alternatively, the hydroxy group of A2 may be converted to the corresponding chloπde using thionyl chlonde, and the resulting compound is πng- closed as descπbed previously in Scheme 1 to provide compounds of formula I wherein Z=S. The starting mateπals for the synthesis depicted Scheme 3 are either commercially available or may be prepared using known organic synthesis methodologies. Scheme 4 H 3 COOC-CH 2 - Ar 1 — Y-CH 2 _ (C H 2 ) n _CH 2 -χ-Ar 2 A1 HX-Ar 2 (X=0) B2 Cs 2 C0 3 , DMF H 3 COOC-CH 2 - Ar 1 — Y-CH 2 - (CH 2 ) n -CH 2 OMs (Y=CH 2 ) .02 1) H 2 , Pd/C, Ethanol 2) (Ms) 2 0, Pyr, CH 2 CI 2 H 3 COOC-CH 2 - Arι -C≡C-(CH 2 )n-CH 2 -χH (X = 0) D2 HC≡C-(CH 2 )n-CH 2 -χ H (χ=0) Pd(PPh 3 ) 4 , CuBr, Et 3 N H 3 COOC-CH 2 - Ar 1 — L L is a leaving group (Tf) 2 0 = Trifluoromethanesulfonic Anhydride, (Ms) 2 0 = Methanesulfonic Anhydride Scheme 4 shows the synthesis of intermediate Al , which contains an Arl moiety and an Ar2 moiety connected by a >4 atom tether in which one of X or Y is oxygen Palladium catalyzed addition of an alkyne to either an arylbromide (El) or inflate (E2) gives DJ_ or D2, respectively Hydrogenation of the alkyne (DI or D2) at atmosphenc pressure afforded the fully saturated matenal, Cl or C^ which was coupled to either B_l or B2 in the presence of an inorganic base (e.g. Cs2CO3) in dimethylformamide solution to provide the tethered arylacetate ester intermediate Al. The starting mateπals for the synthesis depicted in scheme 4 are either commercially available or may be prepared using known organic synthesis methodologies EXAMPLES The following Examples are provided only to illustrate the invention and are not to be construed as limiting the invention in any manner. EXAMPLE 1 5-r3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)phenyll-2,4-thιazohdmedιone Step A: Preparation of 2-propyl-4-cyclohexyl phenol A solution of 4-cyclohexylphenol (lOg), allyl bromide (13.74g) and potassium carbonate (9.42g) in acetone (150 mL) was kept at reflux for 10-12 h. The solution was cooled, filtered and concentrated under reduced pressure to provide 4- cyclohexyl allyloxyphenol (12.4g). This product was used as such for Step C. A solution of 4-cyclohexyl allyloxyphenol (12.3g) in ortho- dichlorobenzene (50 mL) was kept at reflux for 36 h. The mixture was cooled to room temperature and chromatographed over silica gel to afford 2-propenyl-4- cyclohexylphenol (1 l.Og). This matenal was dissolved in methanol (150 mL) and hydrogenated over Pd/C (1.2g) at 50 psi. The reaction was filtered through Cehte and concentrated in vacuo to afford the title compound (1 l .Og). Η NMR (400MHZ, CDC1 ): δ 6.96 (s, IH); 6.93 (d, IH, J=8Hz); 6 7 (d, IH, J=8Hz); 4.51 (s, IH), 2 57 (t, 2H, J=7.6Hz); 2.42 (m, IH); 1.86-1.2 (m, 12H). 0.99 (t, 3H, J=7.2Hz) Step B' Preparation of ethyl 3-(3-bromopropoxy)mandelate A solution of ethyl 3-hydroxymandelate (10.0 g), 1,3-dιbromopropane (41.16 g) and potassium carbonate (8.08 g) m dry DMF (150 mL) was stirred at 40°C overnight. The reaction mixture was partitioned between ethyl acetate and 1.0 N HC1 The organic layer was washed twice with water, once with bπne and then dπed over sodium sulfate. The organic layer was then filtered and the solvent removed in vacuo The resulting oil was chromatographed on silica gel, using a gradient of 100% hexane to methylene chlonde-hexane to yield the titled compound. 1H NMR (400MHz, CDC1 3 ): δ 7.3 (d, IH, J=8.0Hz); 7.03 (d, IH, J=7.6Hz); 7.0 (s, IH); 5.14 (d,lH, J=5.5Hz); 4.28-4.2 (m, 2H); 4.13 (t, 2H, J=5.9Hz); 3.62 (t, 2H, J=6.5Hz); 2.33 (quint, 2H, J=5.8Hz); 1.26 (t, 3H, J=7.0Hz). Step C: Preparation of ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy) propox y)mandel ate A solution of 2-propyl-4-cyclohexylphenol (0.9 g) (as prepared in Step A), potassium carbonate (0.69 g) and ethyl 3-(3-bromopropoxy)mandelate (1.18g) in DMF (30 mL) was stirred at 40°C for 30 h. The reaction mixture was partitioned between ethyl acetate and 1.0 N HC1. The organic layer was washed twice with water, once with bnne and then dπed over sodium sulfate. The organic layer was then filtered and the solvent remove in vacuo. The resulting oil was chromatographed on silica gel, using ethyl acetate/hexane to yield the titled compound. 1H NMR (400MHz, CDCI3): δ 7.3-6.78 (m, 7H); 5.12 (d, IH, J=5.0Hz); 4.27 (q, 2H, J=7.2Hz); 4.19 (t, 2H, J=6.0Hz); 4.14 (t, 2H, J=6.0Hz); 3.42 (d, IH, J= 5.0Hz); 2.57 (t, 2H, J=7.4Hz); 2.43-2.2 (m, 3H); 1.85-1.36 (m, 12H); 1.25 (t, 3H, J=7.2Hz); 0.94 (t, 3H, J=7.3Hz). Step D Preparation of ethyl α-chloro-3-(3-(2-propyl-4-cyclohexylphenoxy) propoxy)phenylacetate Thionyl chloride (0.15mL) was added to a solution of ethyl 4-(3-(2- propyl-4-cyclohexylphenoxy)propoxy) mandelate of Step C (0.71g), pyndine (0.19 mL), and toluene (15 mL). The reaction mixture was stirred 6-7 h and then partitioned between ethyl acetate and water The organic layer was washed twice with water, once with bπne, dned over sodium sulfate, and filtered. The solvent was removed in vacuo and the resulting oil was used as such for the next step. Step E Preparation of 5-[3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy) phenyll-2,4-thιazohdιnedιone The residual oil was dissolved in ethanol ( 15 mL) Thiourea (0.14 g) and sodium acetate (0.14 g) were added The mixture was heated to reflux for 6 h. Hydrochlonc acid (5 mL, 6 N) was added, and the mixture was heated at 115°C for 6 h The mixture was partitioned between ethyl acetate and water. The organic layer was washed twice with water, dned over sodium sulfate, filtered and evaporated to an oil, which was chromatographed over silica gel with 3% acetonitπle in methylene chlonde to afford the title compound. iH NMR (400MHz, CDC1 3 ): δ 8.14 (brs, IH), 7.35-6.8 (m, 7H); 7.02-6.79 (m,8H); 5.32 (s, IH); 4.2 (t, 2H, J=6.3Hz); 4.14 (t, 2H, J=5.8Hz); 2.57 (t, 2H, 7.6Hz); 2.43 (m, IH); 2.28 (quint, 2H, J=6.3Hz); 1.85-1.25 (m, 12H); 0.94 (t, 3H, J=7.5Hz). MS: m/e=466(M + ) EXAMPLE 2 5-r3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)phenyll-2,4-oxazohdinedione Step A Preparation of ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy) propoxy)mandelate This compound was prepared according to the procedure descnbed in EXAMPLE 1. STEPS A-C. Step B: 5-[3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)phenyl]-2,4- oxazo dinedione The above compound (1.5g) was dissolved in absolute ethanol (30 mL) and to this was added sodium ethoxide (1.3 M equivalent) and urea (0.28g). The solution was stirred initially at room temperature and then at reflux for 15 h. After cooling, the solution was concentrated under reduced pressure and the residue was acidified using 6N HC1, extracted with ethyl acetate, washed with water and bnne, and then concentrated. Punfication of the residue using flash chromatography over silica-gel using acetonitnle-dichloromethane afforded the desired compound. l NMR (400MHz, CDC1 ): δ 7.70 (brs, IH); 7.39-6.97 (m, 6H); 6 79 (d, IH, J=8.6Hz); 5.77 (s, IH); 4.21 (t, 2H, J=6.2Hz); 4.14 (t, IH, J=5.8Hz); 2.58 (t, 2H, J=7.4Hz); 2.43 (m, IH); 2.29 (quint, 2H, J=6.1Hz); 1.85-1.23 (m, 12H); 0.94 (t, 3H, J=7.4Hz). MS: m/e=452(M + ) EXAMPLE 3 5-[3-(3-(2-propyl-4-cvclopentylphenoxy)propoxy)phenyll-2.4-thιazohdιnedιone Using 4-cyclopentylphenol, this compound was synthesized in a similar manner as described for the preparation of EXAMPLE 1 (STEPS A-E). *H NMR (300MHz, CDC1 ): δ 8.09 (brs, IH); 7.34-6.79 (m, 7H); 5.31 (s, IH); 4.18 (t, 2H, J=6.1Hz); 4.12 (t, 2H, J=5.9Hz); 2.9 (m, IH); 2.55 (t, 2H, J=7.4Hz); 2.26 (quint, 2H, J=6.0Hz); 2.05-1.49 (m, 10H); 0.92 (t, 3H, J=7.5Hz). MS: m/e=454(M + ) EXAMPLE 4 5-r3-(3-(2-propyl-4-cyclopentylphenoxy)propoxy)phenyll-2,4-oxazolidinedione Beginning with 4-cyclopentylphenol, this target was synthesized in an identical manner to that used for the preparation of EXAMPLE 2. iH NMR (300MHz, CDCI3): δ 7.95 (brs, IH); 7.35 (d, IH, J=7.6Hz); 7.03-6.95 (m, 5H); 6.9 (d, 2H, J=8.5Hz); 5.75 (s, IH); 4.19 (t, 2H, J=6.2Hz); 4.12 (t, 2H, J=5.9Hz); 2.9 (m, IH); 2.55 (t, 2H, J=7.6Hz); 2.27 (quint, 2H, J=6.1HZ); 2.1-1.4 (m, 10H); 0.92 (t, 3H, J=7.3Hz). MS: m/e=438(M + ) EXAMPLE 5 5-r3-(3-(2-chloro-4-cvclopentylphenoxy)propoxy)phenyH-2,4-oxazolidinedione Step A: Preparation of 2-chloro-4-cvclopentylphenol A solution of 4-cyclopentylphenol (4g) and dπsobutylamine (0.35 mL) in toluene (75 mL) was heated to 70 °C with stirnng. Sulfuryl chlonde (2.0 mL) was introduced via synnge and the reaction stirred for 2h at 70 °C, then cooled to room temperature. The reaction mixture was concentrated in vacuo and the resulting oil subjected to chromatography on silica gel using hexane/ethyl acetate eluent to afford the title compound (3.5 g). ^ NMR (400 MHz, CDC1 3 ): δ 7.19 (d, IH, J=2.0 Hz); 7.06 (dd, IH, J=2.2 Hz, 6.2 Hz); 6.94 (d, IH, J=8.6 Hz); 5.37 (s, IH); 2.92 (quint, IH, J = 7.0 Hz); 2.03 (m, 2H); 1.80 (m, 2H); 1.67 (m, 2H); 1.53 (m, 2H). MS: m/e=197(M + ) Step B: Preparation of 5-r3-(3-(2-chloro-4- cvclopentylphenoxy)propoxy)phenvn-2,4-oxazohdmedιone This compound was prepared according to the procedure descnbed in Example 2, Steps A and B. l U NMR (400 MHz, CDCI3): δ 7.83 (brs, IH); 7.28 (t, IH, J=6.1 Hz); 7.24 (d, IH, J=2.1 Hz); 7.08-6.99 (m, 3H); 6.88 (d, IH, J=8.4 Hz); 5.78 (s, IH); 4.21 (t, 2H, J=6.0 Hz); 4.18 (t, 2H, J=6.0 Hz); 2.92 (quint, IH, J = 7.0 Hz); 2.31 (quint., 2H, J=6.1 Hz); 2.03 (m, 2H); 1.80 (m, 2H); 1.67 (m, 2H); 1.53 (m, 2H). MS: m/e=430(M + ) EXAMPLE 6 5-[3-(3-(2-propyl-4-(4',4'-dιfluorocyclohexyl)-phenoxypropoxy)phenyl]-2,4- oxazohdmedione Step A: Preparation of 2-propyl-4-(4',4,-dιfluorocyclohexyl)phenol Commercially available 4-(4-hydroxyphenyl)cyclohexanone was first converted to the corresponding 4-(2-propyl-4-hydroxyphenyl)cyclohexanone according to the procedure descnbed in Example 1 , Step A. To a solution of 4-(2-propyl-4-hydroxyphenyl)cyclohexanone (2.32g) in THF (30 mL) was added at 0°C bιs(2-methoxyethyl)ammo sulfur tπfluoπde (5.5 mL) and the solution was stirred for 36 h. At the end, the reaction mixture was cooled to 0°C and the excess of reagent was carefully destroyed using a saturated solution of NaHCO,. The reaction mixture was diluted with ethyl acetate (150 mL) and the organic phase was washed with water (3 x 50 mL), bπne, dned over sodium sulfate and concentrated under reduced pressure and the resulting oil was chroamatographed on silica gel using a gradient of 100% hexane to ethyl acetate-hexane to yield the title compound. l U NMR (400MHz, CDC1 3 ): δ 6.95 (m, 2H), 6.72 (d, IH, J=8.2Hz); 4.6 (brs, IH); 2.6-1.6 (m, 13H); 0.99 (t, 3H, J=7.2Hz). Step B: Preparation of ethyl 3-(3-(2-propyl-4-(4',4'-dιfluorocyclohexyl)- phenoxypropoxy)mandelate This compound was prepared according to procedure descnbed in Example 1, Steps B-C. Step C: 5-[3-(3-(2-propyl-4-(4',4'-dιfluorocyclohexyl)-phenoxypropoxy)phenyl]-2,4- oxazo dinedione This compound was prepared according to the procedure described in Example 2, STEP B. *H NMR (400MHz, CDC1 3 ): δ 8.03 (brs, IH), 7.4-6.8 (m, 7H); 5.76 (s, IH); 4.2 (t, 2H, J=6.0Hz); 4.15 (t, 2H, J=5.8Hz); 2.57 (t, 2H, 7.4Hz); 2.4-1. (m, 13H); 0.94 (t. 3H, J=7.2Hz). EXAMPLE 7 5-[3-(3-(2-chloro-4-(4',4'-difluorocyclohexyl)-phenoxypropoxy)phenyl]-2,4- oxazolidmedione Step A: Preparation of 2-chloro-4-(4',4,-difluorocyclohexyl) phenol Commercially available 4-(4-hydroxyphenyl)cyclohexanone was first converted to the corresponding gem difluoro analog using bis(2-methoxyethyl)amino sulfur trifluoride according to procedure described in the Example 6, Step A. To a solution of this 4-(4-hydroxyphenyl) -l,l'-difluorocyclohexane (l.lg) in toluene (15 mL) was added diisobutylamine(0.062 mL) and sulfuryl chloride (0.29 mL), and the mixture was stirred at 70°C for 3-4h. Excess reagents were removed under the reduced pressure. The residue was diluted with ethyl acetate and the organic phase was washed with water, saturated solution of NaHCO 3 , then brine, and was then dried over sodium sulfate and concentrated in vacuo to afford a crude oil. The oil was subjected to silica gel chromatography using hexane-dichloromethane to furnish the title compound. Step B: Preparation of ethyl 3-(3-(2-chloro-4-(4',4'-difluorocyclohexyl)- phenoxypropoxy)mandelate This compound was prepared according to procedure descnbed in the Example 1, Step B-C. Step C: 5-[3-(3-(2-chloro-4-(4',4'-difluorocyclohexyl)-phenoxypropoxy)phenyl]-2,4- oxazohdinedione This compound was prepared according to the procedure descnbed in the Example 2, Step B. ] H NMR (400MHz, CDC1 3 ): δ 8.05 (brs, IH), 7.4-6.8 (m, 7H); 5.77 (s, IH); 4.25-4.2 (m, 4H); 4.15 (t, 2H, J=5.8Hz); 2.6-1.6 (m, 11H). EXAMPLE 8 5-13-(3-(2-propyl-4-(4,4-dιmethylcvclohexyl)phenoxy)propoxy)phenyll-2,4- oxazohdinedione Step A: Preparation of 4,4-dimethylcyclohexyl-l-one A solution of 4,4-dimethyl-2-cyclohexene-l-one (5.6g, 0.94mmol) in ethanol (45mL) was degassed and purged with nitrogen, 10% palladium on carbon was added, the reaction was degassed and purged with hydrogen. The mixture was stirred at room temperature overnight under an atmosphere of hydrogen and filtered through cehte. The filtrate was evaporated to afford the title compound (5.0g). 'HNMR (400MHz, CDC1 3 ): δ 2.33-2.37 (t, 4H, J=7.05Hz), 1.64-1.69 (t, 4H, J=6.95Hz), 1.1 (s, 6H). Step B Preparation of 4-(l-hydroxyl-4,4-dιmethylcyclohexyl)allyloxyphenol A solution of dried magnesium (0 583g. 24 Ommol), 1,2- dibromobenzene (3 drops), 4-bromo allyloxyphenol (4 lg, 19.2mmol), in ethyl ethei (20mL) was stirred at reflux for l-2h The solution was cooled and added to a solution of 4,4-dιmethylcyclohexyl-l-one (2.0g, 16 Ommol) in ethyl ether (lOmL) and stirred at reflux for l-2h The reaction mixture was cooled and treated with 2N hydrochloric acid, diluted with ethyl acetate, and washed with water and bnne The organic layer was dned over sodium sulfate, filtered and evaporated to an oil The resulting oil was chromatographed on silica gel, using 100% toluene, to afford the title compound (1 69g) 'HNMR (400MHz, CDC1 3 ) δ 7 46-7 43 (d, 2H), 6.93-9.90 (d, 2H), 6 11-6.04 (m, IH); 5 46-5 27 (dd, 2H); 4 56-4 54 (d, 2H). 2.33-1.21 (m, 8H), 1 1 (s, 6H) Step C. Preparation of 4-(4,4-dιmethyl-l-cyclohexene)aIlyloxyphenol A solution of 4-(l-hydroxyl-4,4-dιmethylcyclohexyl)allyloxyphenol (1.69g), concentrated HC1 (lmL) in ethanol (lOmL) was stirred at 50°C for l-2h The mixture was cooled and partitioned between ethyl acetate and aqueous sodium bicarbonate The organic layer was washed with water, bπne, and dned over sodium sulfate The organic layer was then filtered and the solvent removed in vacuo. The resulting oil was chromatographed on silica gel, using toluene/hexane (1:1), to afford the title compound (0 61 lg) 'HNMR (400MHz, CDC1 3 ): δ 7.35-7.33 (d, 2H), 6.89-6.86 (d, 2H), 6.11-6.00 (m, 2H); 5 99-5.28 (dd, 2H); 4.56-4.53 (d, 2H); 2.42-2.40 (m, 2H); 2.01- 1.99 (m, 2H); 1.56-1.51 (t, 2H, J=6.5Hz); 0.970 (s, 6H) Step D: Preparation of 2-allyl-4-(4,4-dιmethyl-l-cyclohexene) phenol A solution of 4-(4,4-dιmethyl-l-cyclohexene)allyloxyphenol (0.61 lg) in tπchlorobenzene was stirred at reflux overnight. The mixture was cooled to room temperature and chromatographed over silica gel, using methylene chloπde/hexane (1:1), to afford the title compound (0.389g) ! HNMR (400MHz, CDC1 3 ): δ 7.24-7.17 (m, 2H); 6.78-6.76 (d, IH); 6.05-5.97 (m, 2H); 5.21-5.16 (m, 2H); 4.89 (s, IH); 3.43-3.42 (d, 2H); 2.42-2.37 (m, 2H); 2.01-1.97 (m, 2H); 1.54-1.51 (m, 2H); 0.97 (s, 6H) Step E Preparation of 2-propyl-4-(4,4-dιmethylcyclohexy]) phenol A solution of 2-allyl-4-(4,4-dιmethyl-l-cyclohexene)phenol (0.389g) in ethyl acetate (lOmL) was degassed and purged with nitrogen, 10% palladium on carbon was added, the reaction was degassed and purged with hydrogen. The mixture was stirred at room temperature overnight under an atmosphere of hydrogen and filtered through cehte. The filtrate was evaporated to afford the title compound (0.369g) 'HNMR (400MHz, CDC1 3 ): δ 6.98-6 94 (m, 2H); 6.72-6.70 (d. IH); 4 50 (s. IH), 2.60-2.56 (t, 2H, J=7.7Hz); 2.34 (m, IH), 1 69-1 27 (m, 10H); 0.983 (s, 6H) Step F 5-r3-(3-(2-propyl-4-(4,4- dιmethylcvclohexyl)phenoxy)propoxy)phenyn-2,4-oxazohdιnedιone The title compound was prepared according to the method descπbed in Example 2 steps A and B, using 2-propyl-4-(4,4-dιmethylcyclohexyl)phenol as the starting matenal in step A 'HNMR (400MHz, CDC1 3 ): δ 7.79 (bs, IH); 7.38-7.34 (m,lH); 7.24- 7.00 (m, 5H); 6.99-6.78 (d, IH); 5.75 (s, IH); 4.22-4.19 (t, 2H, J=6.1Hz); 4.15-4.12 (t, 2H. J=6.0Hz), 2.59-2.55 (t, 2H, J=7.5Hz); 2.30-2.20 (m, 3H); 1.69-1.29 (m, 10H); 0.983-0.857(s, 9H). MS: m/e=502 (m+Na) EXAMPLE 9 5-[3-(3-(2-chloro-4-(4,4-dιmethy]cvclohexyl)phenoxy)propoxy)phenyll-2,4- oxazohdinedione Step A Preparation of 4-(l-hydroxyl-4,4-dιmethylcyclohexyl)anιsole A solution of 4-methoxyphenylmagnesιum bromide (56mL, 27.8mmol), 4,4-dιmethylcyclohexyl-l-one (3.2g, 25 4mmol), in THF (30mL) was stirred at room temperature overnight. The reaction mixture was treated with 2N hydrochlonc acid and diluted with ethyl acetate. The organic layer was washed with water and bnne, dπed over sodium sulfate, filtered and evaporated to an oil. The resulting oil was chromatographed on silica gel, using a gradient of toluene / ethyl acetate (18 1), to afford the title compound (1 77g) Η NMR (400MHz, CDC ): δ 7.45 (d, 2H); 6.91 (d, 2H); 3.82 (s, 3H); 2 01-1.96 (m, 2H); 1.72-1.66 (m, 3H), 1.54-1 51 (m, 2H), 1.33-1.31 (m, 2H), 1.1-1.01 (d, 6H) Step B" Preparation of 4-(4,4-dιmethyl-l-cyclohexene)anιsole Using 4-(l-hyroxyl-4,4-dιmethylcyclohexyl)anιsole, this compound was prepared in a similar manner as descπbed for the preparation of EXAMPLE 8 (STEP C) (5.9g). Η NMR (400MHz, CDC1 3 ): δ 7.35-7.34 (d, 2H); 6.87-6.85 (d, 2H), 5.99-5.97 (bs, IH); 3.82 (s, 3H); 2.42-2.40 (m, 2H), 2 0-1.98 (m, 2H); 1.54-1.51 (t, 2H); 0.968 (s, 6H); Step C. Preparation of 4-(4,4-dιmethylcyclohexyl)anιsole Using 4-(4,4-dιmethyl-l-cyclohexene)anιsole, this compound was prepared in a similar manner as descnbed for the preparation of EXAMPLE 8 (STEP A) (5.7g). Η NMR (400MHz, CDC1 3 ): δ 7.17-7.15 (d, 2H); 6.86-6.84 (d, 2H); 3.81 (s, 3H); 2.41-2.35 (m, IH); 1.70-1.30 (m, 8H); 0.968 (d, 6H); Step D: Preparation of 4-(4,4-dιmethylcyclohexyl)phenol A solution of 4-(4,4-dιmethylcyclohexyl)anιsole (2.76g, 12.64mmol), boron tπ bromide (4.42mL, 15.2mmol), in methylene chloπde was stirred at room temperature overnight. The reaction mixture was treated with wet ice and diluted with methylene chloπde. The organic layer was washed with water and bπne. The organic layer was dned over sodium sulfate, filtered, and concentrated in vacuo. The product was chromatographed on silica gel, using toluene / ethyl acetate (18:1), to afford the title compound (2.19g). Η NMR (400MHz, CDCI3): δ 7.27-7.10 (d, 2H); 6.78-6.76 (d, 2H): 2 37-2.33 (m, IH); 1.69-1.29 (m, 8H); 0.78-0.961 (d, 6H); Step E- Preparation of 2-chloro-4-(4,4-dιmethylcyclohexyl)phenol A solution of 4-(4,4-dιmethylcyclohexyl)phenol (2.16g, 10.6mmol). disiobutylamme (0.14 mL) and sulfuryl chlonde (0.59 mL, 7.4mmol) in toluene was stirred at 70°C for 2h. The reaction mixture was cooled to room temperature, treated with saturated aqueous sodium bicarbonate and diluted with ethyl acetate. The organic layer was washed with water, bπne, dπed over sodium sulfate, filtered and concentrated in vacuo. The resulting oil was subjected to chromatography on silica gel, using hexane / ethyl acetate (20: 1), to afford the title compound (1.7g). 1H NMR (400MHz, CDC1 3 ): δ 7.18 (s, IH); 7.05-7.03 (d, IH); 6.95- 6.93 (d, IH); 5.36 (s, IH), 2.37-2.30 (m, IH); 1.69-1.29 (m, 8H); 0.976-0.850 (d, 6H); Step F: 5-r3-(3-(2-chloro-4-(4,4- dιmethylcvclohexyl)phenoxy)propoxy)phenyIl-2,4-oxazohdιnedιone The title compound was prepared according to the method descπbed in Example 2 steps A and B, using 2-chloro-4-(4,4-dιmethylcyclohexyl)phenol, as the starting matenal in step A. 1H NMR (400MHz, CDC1 3 ): δ 7.80 (brs, IH); 7.38-6.87 (m,7H); 5.74 (s, IH); 4.25-4.19 (m, 4H); 2.35-2.29 (m, 3H); 1.68-1.27 (m, 8H); 0.973-0.958 (d, 6H). MS: m/e=494 (M+Na) EXAMPLE 10 5-[3-(3-(2-propyl-4-(morpholinyl)phenoxy)propoxy)phenyll-2,4-oxazolidinedione Step A- Preparation of 2-propyl-4-morphohnyl-l-benzyloxybenzene A solution of 3-propyl-4-benzyloxy-l-bromobenzene (l.Og, 3.3mmol), morphohne (0.5g, 6.6mmol), Pd(OAc) 2 (0 036g, O. lόmmol), BINAP (0.082g, 0 132mmol) and cesium carbonate (1.50g, 4.62mmol) in toluene (134mL) was degassed and purged with nitrogen. The reaction mixture was stirred at 100°C overnight. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and 10% aqueous citπc acid. The organic layer was washed with water and bπne. The organic layer was dned over sodium sulfate, filtered and evaporated to an oil. The resulting oil was chromatographed on silica gel, using toluene with 5% ethyl acetate, to afford the title compound (1.03g) Η NMR (400MHz, CDC1 3 ) δ 7.45-6.70 (m, 8H); 5.04 (s, 2H); 3.88- 3.86 (m, 4H); 3 09-3.06 (m, 4H); 2.66-2.62 (t, 2H) 1.68-1.65 (q, 2H); 0.990-0.953 (t, 3H) Step B: Preparation of 2-propyl-4-morphohnyl phenol A solution of 2-propyl-4-morphohnyl-l-benzyloxybenzene (.081 lg) in ethyl acetate (10mL)/acetιc acid (2mL) was degassed and purged with nitrogen, 10% palladium on carbon was added, the reaction mixture was degassed and purged with hydrogen. The mixture was stirred at room temperature overnight under an atmosphere of hydrogen and filtered through ce te. The filtrate was evaporated to afford the title compound (0.430g). Η NMR (400MHz, CDC1 3 ): δ 6.75-6.67 (m, 3H); 4.45 (s, IH); 3.88- 3.86 (m, 4H); 3.07-3.05 (m, 4H); 2.59-2.55 (t, 2H) 1.68-1.62 (q, 2H); 1.01-0.975 (t, 3H). Step C: 5-r3-(3-(2-propyl-4-(morpholιnyl)phenoxy)propoxy)phenyl ~ |-2.4- oxazo dinedione The title compound was prepared according to the method descnbed in Example 2 steps A and B, using 2-propyl-4-morphohnyl phenol as the starting matenal in step A. 1H NMR (400MHz, CDC1 3 ): δ 7.37-7.35 (t, IH); 7.02-6.72 (m, 7H); 5.74 (s, IH); 4.20-4.11 (dt, 4H); 3.89-3.87 (m, 4H); 3.09-3.07 (m, 4H); 2.57-2.53 (t, 2H): 2.28-2.25 (t, 2H, J=6.1Hz); 1.60-1.55 (q, 2H, J=7.4Hz); 0.939-0.903 (t, 3H, J=7.2Hz). MS: m/e=455.4 (M+) EXAMPLE 11 5-r3-(3-(2-Propyl-4-(4-tetrahyropyranyl)-phenoxy)propoxy)phenyll-2,4- oxazohdinedione Step A: 4-Bromo-2-propylphenol The title compound was prepared from 4-bromophenol following the procedure descnbed in Example 1 Step A, except that the hydrogenation was conducted using platinum oxide as catalyst, ethyl acetate as solvent, under 30psι hydrogen pressure. 4-bromo-2-propylphenol: Η NMR (500MHz, CDC1 3 ): δ δ7.25 (d, J=2.5Hz, IH), 7.19 (dd, J= 2.5Hz, 8.5Hz, IH), 6.66 (d, J=8.5Hz, IH), 4.72 (brs, IH), 2.56 (t, J=7.3Hz, 2H), 1.65 (seq., J=7.6Hz, 2H), 0.99 (t, J=7.3Hz, 3H). Step B: Benzyl 2-Propyl-4-(4-(4-hyroxyl-tetrahvdropyranyl))phenyl ether To a 100ml acetone solution of 4-bromo-2-propylphenol 5.4g (25.1mmol) and benzyl bromide 5.6g (32 7mmol) was added potassium carbonate 5 2g (37 6mmo) Resulting suspension was stirred under reflux temperature for overnight. Acetone was removed under reduced pressure, diluted with ethyl acetate and water Organic phase was separated. Aqueous phase was extracted with ethyl acetate twice The combined organic phases were dned over anhydrous sodium sulfate, filtered, concentrated, chromatographed on silica gel (hexanes t-butyl methyl ether) to give 6 96g of benzyl 4-bromo-2-propylphenyl ether as colorless oil To a 2ml dry THF suspension of magnesium turnings 750mg (30.9mmol) was slowly added benzyl 4-bromo-2-propylphenyl ether 3 5g (11.5mmol) over 30mιn with occasional heating by a heat gun and addition of 13ml of dry THF After the addition was complete, resulting dark gray suspension was heated to 40- 50°C for lhr To resulting suspension of 4-benzyloxy-2-propylphenyl magnesium bromide was added 15ml of dry THF solution of tetrahydro-4H-pyran-4-one 861mg (8 63mmol) while cooled in a ice-water bath After stirnng overnight at rt, THF was removed under reduced pressure, diluted with ethyl acetate and saturated aqueous ammonium chloπde solution. Organic phase was separated Aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dned over anhydrous sodium sulfate, filtered, concentrated, chromatographed on silica gel (hexanes : ethyl acetate) to give 1.88g of the title compound as white solid. Benzyl 2-Propyl-4-(4-(4-hyroxyl-tetrahydropyrayl)) phenyl ether 1H NMR (500MHz, CDC1 3 ): δ 7.46-7.32 (m, 5H), 7.31 (d, J=2.4Hz, IH), 7.27 (dd, J=2.4Hz, 8.5Hz, IH), 6.90 (d, J=8.5Hz, IH), 5.12 (s, 2H), 4.0-3 8 (m, 4H), 2.69 (t, J=7.7Hz, 2H), 2.21-2.15 (m, 2H), 1.76-1.62 (m, 4H), 0.98 (t, J=7.4Hz, 3H). StepC: 2-Propyl-4-(4-tetrahydropyranyl)phenol To a 30ml 1,2-dιchloroethane solution of benzyl 2-propyl-4-(4-(4- hyroxyl-tetrahydropyranyl))phenyl etherl.85g (567mmol) were added diisopropyl ethyl amine 2.4ml (13.8mmol), and methanesulfomc anhydnde 1.28g (7.34mmol). After stirnng at rt overnight, the solvent was removed under reduced pressure, diluted with ethyl acetate and water. Organic phase was separated. Aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dπed over anhydrous sodium sulfate, filtered, concentrated, chromatographed on silica gel (hexanes t-butyl methyl ether) to give 0.875g of benzyl 2-propyl-4-(4-(5,6-dιhyro- 2H-pryanyl))phenyl ether. Benzyl 2-propyl-4-(4-(5,6-dιhyro-2H-pryanyl))phenyl ether: 1H NMR (500MHz, CDC1 3 ): δ 7.48-7.32 (m, 5H), 7.24 (d, J=2.4Hz, IH), 7.19 (dd, J=2 4Hz, 8.5Hz, IH), 6.88 (d, J=8.5Hz, IH), 6.04 (brs, IH), 5.11 (s, 2H), 4.33 (app. q., J=2 7Hz, 2H), 3 95 (app. t., 2H), 2.69 (t, J=7.5Hz, 2H), 2.52 (brs, 2H), 1.68 (seq., J=7.5Hz, 2H), 0.99 (t., J=7.4Hz, 3H). To a 30ml 190-proof ethanol solution of benzyl 2-propyl-4-(4-(5,6- dιhyro-2H-pryanyl))phenyl ether 0.875g (2.84mmol) was added 10% Pd/C 45mg This suspension was placed in a Parr shaker under a hydrogen atmosphere (50psι) overnight. The reaction mixture was filtered through cehte, concentrated, chromatographed on Silica gel (hexanes: ethyl acetate) to give 0.573g of the title compound. 2-Propyl-4-(4-tetrahydropyrayl)-phenol: Η NMR (500MHz, CDC1 3 ): δ 6.98 (d, J=2.3Hz, IH), 6.94 (dd, J=2.3Hz, 8Hz, IH), 6.73 (d, J=8Hz, IH), 4.08 (m, 2H), 3.52 (t, J=7.4Hz, 2H), 2.7-2.55 (m, 4H), 1.75 (m, 3H), 1.66 (seq., J=7.4Hz, 2H), 1.00 (t, J=7 4Hz, 3H). Step D: 5-[3-(3-(2-Propyl-4-(4-tetrahyropyranyl)-phenoxy)propoxy)phenyll- 2,4-oxazohdmedιone 2-Propyl-4-(4-tetrahydropyrayl)phenol was treated as descπbed in Example 1 Step C-E, to give the title compound . 5-[3-(3-(2-Propyl-4-(4-tetrahyropyranyl)phenoxy)propoxy)phenyl]-2,4- oxazohdinedione; 1H NMR (500MHz, CDC1 3 ): δ8.08 (brs, IH), 7.36 (app.t., J=8Hz, IH), 7.04-6.86 (m, 4H), 6.82 (d, J=8Hz, IH), 5.77 (s, IH), 4.21 (t, J=6.2Hz, 2H), 4.15 (t, J=6.2Hz, 2H), 4.08 (dd, J=3.5Hz, 11.1Hz, 2H), 3.53 (dt, J=2.5Hz, 9Hz), 2.69 (m, IH), 2.58 (t, J=7.6Hz, 2H), 1.8-1.7 (m, 4H), 1.65-1.55 (m, 4H), 0.94 (t, J=7.3Hz, 3H). MS m/e= 454(M++H) EXAMPLE 12 5-[3-(3-(2-Chloro-4-(4-tetrahyropyranyl)phenoxy)propoxy)phenyn-2,4- oxazohdinedione Step A 4-(4-Tetrahydropyranyl)-phenol 4-Bromo phenol was treated as described in EXAPLE 11 Step B-C to give the title compound. 4-(4-Tetrahydropyranyl)phenol: 1H NMR (500MHz, CDC1 3 ): δ 7.11 (d, J=8.5 Hz, 2H), 6.81 (d, J=8.5Hz, 2H), 5.03 (brs. IH), 4.10 (app.d, 2H), 3.55 (app.dt, 2H), 2.71 (tt, lH), 1.85-1.75 (m, 4H). Step B: 2-Chloro-4-(4-tetrahydropyranyl)phenol To a 30ml Toluene solution of 4-(4-tetrahydropyranyl) phenol lg (5 61 mmol) and dnsobutylamine 0.08ml (0.46mmol) was added sulfuryl chloπde 0.51ml (6.35mmol) over 3hr peπod upon heating at 70°C. Stimng was continued at that temp, for 2hr after the addition of sulfuryl chloπde was complete. The solvent was removed under reduced pressure, diluted with ethyl acetate and washed with 2N aqueous HCl, saturated aqueous sodium bicarbonate solution, dπed over anhydrous sodium sulfate, filtered, concentrated, chromatographed on silica gel (hexanes : ethyl acetate) to give 0.94 lg of the title compound as while solid. 2-Chloro-4-(4-tetrahydropyranyl)phenol: 1H NMR (500MHz, CDC1 3 ): δ 7.19 (s, IH), 7.06 (d, J=8.5Hz, IH), 6.99 (d, J=8.5Hz, IH), 5.44 (brs, IH), 4.09 (app.d, 2H), 3.53 (m, 2H), 2.70 (tt, IH), 1.80 (m, 4H). Step C: 5-r3-(3-(2-Chloro-4-(4-tetrahyropyranyl)-phenoxy)propoxy)phenyll- 2,4-oxazohdιnedιone 2-Chloro-4-(4-tetrahydropyranyl)phenol was treated as descπbed in Example 2 Step A-B to give the title compound. 5-[3-(3-(2-Chloro-4-(4-tetrahyropyranyl)phenoxy)propoxy)phenyl]-2,4- oxazohdinedione: Η NMR (500MHz, CDC1 3 ): δ 8.67 (brs, IH), 7.34 (t, J=8.4Hz, IH), 7.24 (d, J=2.1Hz, 1H),7.08 (dd, J=2.1Hz, 8.4Hz, IH), 7.04 (d, J=7.8Hz, IH), 7.00 (s, IH), 6.93 (d, J=8.4Hz, IH), 5.78 (s, IH), 4.26 (m, 4H), 4.11 (d, J=l 1Hz, 2H), 3.54 (m, 2H), 2.71 (tt, IH), 2.33 (app. seq. 2H), 1.77 (m, 4H). MS m/e =446(M++H).

Claims: WHAT IS CLAIMED IS 1 A compound having the formula I CH 9 'X-Ar 2 where Arl 1S (1) arylene or (2) heteroarylene, wherein said arylene or heteroarylene is optionally substituted with from 1 to 4 groups independently selected from Ra, R, or a mixture thereof. (2) heteroaryl, wherein said aryl or heteroaryl is substituted with 1-2 groups independently selected from R, provided that if only one cycloalkyl is present on Ar2, the cycloalkyl is not in the ortho position, and said aryl or heteroaryl is optionally further substituted with from 1-3 groups independently selected from R&; X and Y are independently O, S, N-Rb or CH2, R is (1) C3-8 cycloalkyl, optionally substituted with 1-15 halogen atoms, 1-3 groups independently selected from Ci-6 alkyl, and mixtures thereof; or (2) a 3-10 membered heterocycle containing one or more heteroatoms selected from N, S, O, and SO2, said heterocycle being optionally substituted with 1-3 halogen atoms or one to three Cι_6 alkyl groups; Ra is (1) C i-i 5 alkanoyl, (2) Ci-1 alkyl, (3) C2-15 alkenyl, (4) C2-15 alkynyl, (5) halo, (6) OR b , (7) aryl, or (8) heteroaryl, wherein said alkyl, alkenyl, alkynyl, and alkanoyl are optionally substituted with from 1-5 groups selected from R c , and said aryl and heteroaryl are optionally substituted with 1 to 5 groups selected from Rd, Rb is (1) hydrogen, (2) Ci-ioalkyl, (3) C2-10alkenyl, (4) C 2 -10alkynyl, (5) aryl, (6) heteroaryl, (7) aryl C i-i 5 alkyl, (8) heteroaryl Ci-15 alkyl, (9) Ci-15 alkanoyl, (10) C3-8 cycloalkyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R c , and said cycloalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from Rd, RC is (1) halo, (2) aryl, (3) heteroaryl ; (4) CN, (5) NO 2 , (6) OR f , (7) S(O) m R f , m = 0, 1 or 2, provided that R f is not (8) NR f R f , (9) NRfC0R f , (10) NR f CO2R f , (11) NRfCON(R f )2, (12) NR f SO2R f , provided that Rf is not H, (13) COR f , (14) CO 2 R f , (15) CON(R f ) 2 , (17) OCON(R f )2, or (18) C3_8cycloalkyl, where said cycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 3 groups independently selected from halo and Ci-6 alkyl; Rd is (1) a group selected from Rc, (2) Ci-io alkyl, (3) C2- 10 alkenyl, (4) C2-10 alkynyl, (5) aryl Ci-io alkyl, or (6) heteroaryl Ci-io alkyl, wherein said alkyl, alkenyl, alkynyl, aryl Cj-io alkyl, and heteroaryl Ci-io alkyl are optionally substituted with a group independently selected from R e ; Re is (1) halogen, (2) amino, (3) carboxy, (4) Cι_4alkyl, (5) Cι_4alkoxy, (6) hydroxy, (7) aryl, (8) aryl C 1-4 alkyl, or (9) aryloxy; Rf is (1) hydrogen, (2) Ci-io alkyl, (3) C2-10 alkenyl, (4) C2-10 alkynyl, (5) aryl, (6) heteroaryl, (7) aryl C M5 alkyl, (8) heteroaryl C i-i 5 alkyl, (9) Ci-15 alkanoyl, (10) C3-8 cycloalkyl, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkanoyl and cycloalkyl are optionally substituted with one to four groups independently selected from R e ; or a pharmaceutically acceptable salt thereof 2 A compound of Claim 1 wherein Z is sulfur 3. A compound of Claim 1, wherein Z is O. 4 A compound of Claim 1 wherein Arl ι S arylene optionally substituted with 1-4 groups independently selected from R a , R, or a mixture thereof. 5. A compound of Claim 1 wherein Arl 1S phenylene optionally substituted with 1-2 groups independently selected from halogen and Ci-4 alkyl. 6. A compound of Claim 1 wherein X and Y are independently CH2, O or S 7. A compound of Claim 5 wherem X and Y are each O or S. 8. A compound of Claim 1, wherein Ar2 is aryl, wherein said aryl is substituted with one R a group in the position ortho to X and is further substituted with 1-2 groups independently selected from R and optionally 1-2 groups independently selected from Ra. 9. A compound of Claim 8 wherem said Ra that is in the position ortho to X is selected from the group consisting of (1 ) C3-10 alkyl optionally substituted with 1-4 groups independently selected from halo and C3_6cycloalkyl, (2) C3- 10 alkenyl, 01 (3) C3-8 cycloalkyl 10 A compound of Claim 9 where Ar2 is a phenyl πng 11 A compound according to Claim 10, wherein two of the optional substituents R a are on adjacent carbon atoms in said Ar2 phenyl nng and are joined to form a 5- or 6-membered aromatic heterocychc πng fused to Ar2, said πng containing 1-2 heteroatoms independently selected from N, O, and S(O)m, where m is 0-2, said heterocychc nng and Ar2 together being substituted with 1-2 groups independently selected from R, one R a group in the position ortho to X, and optionally 1-2 additional groups independently selected from R a . 12. A compound according to Claim 11, wherem said aromatic heterocychc πng fused to Ar2 is selected from isoxazole, thiophene, thiophene S- oxide, thiophene S-dioxide, and furan 13. A compound of Claim 1 wherein n is 1 or 2. 14. A compound of Claim 1 having the formula la: la wherem X, Y, Z, n, R, and R a are as in Claim 1. 15. A compound of Claim 14 wherein Z is S. 16 A compound of Claim 14 wherein Z is O 17 A compound of Claim 14 wherein Y is S or O, and X is O 18 A compound of Claim 14 wherein one Ra group is ortho to X and is C3-4 alkyl 19 A compound of Claim 14 wherein n is 1 or 2 20 A compound of Claim 14 wherein Z is O or S, (2) S, and one group Ra is ortho to X and is C3-4 alkyl 21 A compound of Claim 20 wherein Z is O and R is cyclohexyl 22 A compound of Claim 1 selected from the group consisting of the compounds of Examples 1-12 23 A pharmaceutical composition compnsing a compound of Claim 1 and a pharmaceutically acceptable earner 24 A method for treating or controlling diabetes melhtus in a mammal which compnses administeπng to said mammal a therapeutically effective amount of a compound of Claim 1 25 A method for treating, controlling or preventing hyperglycemia in a mammal which compπses admmistenng to said mammal a therapeutically effective amount of a compound of Claim 1 26 A method for treating, controlling or preventing hyperlipidemia in a mammal which compnses admmistenng to said mammal a therapeutically effective amount of a compound of Claim 1. 27 A method for treating, controlling or preventing obesity in a mammal which compπses admmistenng to said mammal a therapeutically effective amount of a compound of Claim 1. 28. A method for treating, controlling or preventing hypercholesterolemia in a mammal which comprises administeπng to said mammal a therapeutically effective amount of a compound of Claim 1. 29. A method for treating, controlling or preventing hypertπglyceπdemia in a mammal which compnses admmistenng to said mammal a therapeutically effective amount of a compound of Claim 1. 30. A method for treating, controlling or preventing dyshpidemia in a mammal which compnses administeπng to said mammal a therapeutically effective amount of a compound of Claim 1.

Inventors: BERGMAN JEFFREY P, DESAI RANJIT C, KOYAMA HIROO, LOMBARDO VICTORIA K, METZGER EDWARD J, SAHOO SOUYMA P, BERGMAN, JEFFREY, P., DESAI, RANJIT, C., KOYAMA, HIROO, LOMBARDO, VICTORIA, K., METZGER, EDWARD, J., SAHOO, SOUYMA, P.
Applicants: BERGMAN JEFFREY P, DESAI RANJIT C, KOYAMA HIROO, LOMBARDO VICTORIA K, MERCK & CO INC, METZGER EDWARD J, SAHOO SOUYMA P, BERGMAN, JEFFREY, P., DESAI, RANJIT, C., KOYAMA, HIROO, LOMBARDO, VICTORIA, K., MERCK & CO., INC., METZGER, EDWARD, J., SAHOO, SOUYMA, P.
Application year: 2000
Main classification: A61K31
IPC codes: A61K31, A61P1, A61P3, A61P9, A61P15, A61P35, A61P43, C07D263, C07D277, C07D413